Katerina Fialkovskaya

Carevive Systems, founded in 2013, is an oncology-centered health technology company committed to understanding and improving the patient experience. Our platform enables providers to monitor patient symptoms remotely using electronic patient-reported outcomes (ePROs) and to provide timely interventions that improve survival outcomes and patient quality of life. The use of Carevive in the cancer clinic unlocks critical data on the real-world patient experience. Carevive leverages these data to continuously improve patient care and advance cancer drug development.

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

Common Sensing is building the next generation of accessible smart health technology for people who use disposable pen-injectors. Based in Cambridge, MA, our team has a progressive and authentic culture where strong teamwork builds the foundation of everything we do. Our Gocap® System utilizes a smart cap for disposable pen-injectors that automatically sends drug-delivery data to a connected phone app.

Bolt is a pre-seed venture firm investing where the digital and physical world intersect. Bolt invests early and with conviction, leading or co-leading the first round of financing in over 90% of our portfolio companies. Bolt has invested in over 70 companies and is currently investing from our $82M Fund III.

First Derm is changing the field of dermatology. We have a portfolio of dermatology applications that provide both consumers and businesses a faster, more convenient means to receive professional advice on skin care. Dermatologists are overloaded with patients and it takes weeks to get an appointment. After sending in an image our users are "triaged"​ by a dermatologist within 24 hours with a possible diagnosis & treatment. 70+% of the users skin conditions can be treated at home or with over the counter medications; there is an enormous cost savings to the user and allows dermatologists to take cases that matter. In our business side, we have developed a HIPAA-compliant researched platform that streamline primary healthcare patients to dermatologists. We have had over 300 000 app downloads to date and 30000 answered queries from all over the world: Sierra Leone, Sydney, Dubai, Delhi, Stockholm, Berlin, Lyon, Madrid, Mexico city, Rio De Janeiro, Chicago, San Francisco etc. 70% of our users are given self treatment advice, 30% are advised to see a doctor for further tests and examination (preventing patients delay). We have built a database on ICD coded images that can be used for machine learning. We have a preliminary Artificial Intelligence (AI) that can identify 33 skin diseases. In 24 months our AI will be better than any dermatologist at diagnosing skin diseases.

Next generation point-of-care diagnostics

MobileODT is driven by a mission: to deliver affordable, practical healthcare innovation and make a difference in the world. Now. We do it through the creation of breakthrough optical diagnostic devices and software services focused on early cancer detection and, soon, a range of other medical purposes. We deliver it at a cost that enables rapid uptake and wide utilization everywhere, but particularly in low-resource settings, where the need is most acute and the impact can be immediate. DISRUPTING TO ADVANCE HEALTHCARE MobileODT is blazing a path similar to disruptive technologies in other markets: We leverage the ubiquity and native capability of smartphones to do something that’s never been done before, replacing complex and cost-prohibitive systems with simplicity and affordability. We create highly advanced optical technology components to turn the smartphone into a mobile, easy-to-use point-of-care tool to help detect cancer and capture a range of biomedical images for diagnostic and other analytical purposes. And we develop intuitive app-based programs to operate our devices and connect to a cloud-based software platform that enables exciting capabilities that could not be imagined just a few years ago — from immediate remote expert consultations to improved case management and, importantly, to easy integration with the range of emerging electronic health records programs. ​FIRST FOCUS: CERVICAL CANCER SCREENING MobileODT’s technology is a potentially game-changing solution to reduce cervical cancer, a global health priority that requires approximately 700 million screenings per year. Our Cervical Cancer Screening System has met with enthusiastic response in eight pilot markets around the world.

Over the past decade we have transformed into a focused leader in health technology. At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patients recovery at home in the community. All supported by a seamless flow of data. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better. Visit our website: http://www.philips.com/ Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html

Carevive Systems, founded in 2013, is an oncology-centered health technology company committed to understanding and improving the patient experience. Our platform enables providers to monitor patient symptoms remotely using electronic patient-reported outcomes (ePROs) and to provide timely interventions that improve survival outcomes and patient quality of life. The use of Carevive in the cancer clinic unlocks critical data on the real-world patient experience. Carevive leverages these data to continuously improve patient care and advance cancer drug development.

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

Common Sensing is building the next generation of accessible smart health technology for people who use disposable pen-injectors. Based in Cambridge, MA, our team has a progressive and authentic culture where strong teamwork builds the foundation of everything we do. Our Gocap® System utilizes a smart cap for disposable pen-injectors that automatically sends drug-delivery data to a connected phone app.

MPM BioImpact is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM BioImpact strives to power novel medical breakthroughs that transform patients’ lives. MPM BioImpact invests across the biotech landscape from early stage start-ups to public companies.